Non-alcoholic fatty liver disease historical perspective: Difference between revisions
| Line 8: | Line 8: | ||
==Historical Perspective== | ==Historical Perspective== | ||
*In 1980, NAFLD was | *In 1980, NAFLD was introduced as a new concept in medical history.<ref>Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-438. PMID 7382552.</ref><ref name="pmid28507929">{{cite journal |vauthors=Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J |title=Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies |journal=J Clin Transl Hepatol |volume=5 |issue=1 |pages=67–75 |year=2017 |pmid=28507929 |pmc=5411359 |doi=10.14218/JCTH.2016.00061 |url=}}</ref><ref name="pmid285079292">{{cite journal |vauthors=Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J |title=Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies |journal=J Clin Transl Hepatol |volume=5 |issue=1 |pages=67–75 |year=2017 |pmid=28507929 |pmc=5411359 |doi=10.14218/JCTH.2016.00061 |url=}}</ref><ref>Day, CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut. 2002 May; 50(5): 585–588.</ref> | ||
* | *The association between obesity and NAFLD was made during 1979 by Adler & Schaffner by extending the clinical picture of NASH. | ||
*In an intensive literature seek of 41 papers.published before 1984, reporting on 1515 morbidly overweight sufferers, Andersen & Gluud reported excess fat in 80%,‘‘parenchymal necrosis’’ in 5–63%, fibrosis in 29% and cirrhosis in 3%.<ref name="urlac-els-cdn-com.ezp-prod1.hul.harvard.edu">{{cite web |url=https://ac-els-cdn-com.ezp-prod1.hul.harvard.edu/S0168827898800731/1-s2.0-S0168827898800731-main.pdf?_tid=1d58f5a0-e34a-11e7-894f-00000aab0f26&acdnat=1513529492_9ccae8522acc090e67ec12bca120b87e |title=ac-els-cdn-com.ezp-prod1.hul.harvard.edu |format= |work= |accessdate=}}</ref> | |||
==References== | ==References== | ||
Revision as of 23:04, 17 December 2017
|
Non-Alcoholic Fatty Liver Disease Microchapters |
|
Differentiating Non-Alcoholic Fatty Liver Disease from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case studies |
|
Non-alcoholic fatty liver disease historical perspective On the Web |
|
American Roentgen Ray Society Images of Non-alcoholic fatty liver disease historical perspective |
|
FDA on Non-alcoholic fatty liver disease historical perspective |
|
CDC on Non-alcoholic fatty liver disease historical perspective |
|
Non-alcoholic fatty liver disease historical perspective in the news |
|
Blogs on Non-alcoholic fatty liver disease historical perspective |
|
Directions to Hospitals Treating Non-alcoholic fatty liver disease |
|
Risk calculators and risk factors for Non-alcoholic fatty liver disease historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]
Overview
NAFLD/NASH was first described as a medical entity in a 1980. Though its histological capabilities had lengthy been recognized , the time period non-alcoholic steatohepatitis (NASH) became first used by Ludwig et al. as recently as 1980 .Ludwig et al. described ‘‘the pathological and medical features of non-alcoholic disease of the liver related with the pathological features maximum generally seen inside the alcoholic liver disorder itself.
Historical Perspective
- In 1980, NAFLD was introduced as a new concept in medical history.[1][2][3][4]
- The association between obesity and NAFLD was made during 1979 by Adler & Schaffner by extending the clinical picture of NASH.
- In an intensive literature seek of 41 papers.published before 1984, reporting on 1515 morbidly overweight sufferers, Andersen & Gluud reported excess fat in 80%,‘‘parenchymal necrosis’’ in 5–63%, fibrosis in 29% and cirrhosis in 3%.[5]
References
- ↑ Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-438. PMID 7382552.
- ↑ Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J (2017). "Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies". J Clin Transl Hepatol. 5 (1): 67–75. doi:10.14218/JCTH.2016.00061. PMC 5411359. PMID 28507929.
- ↑ Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J (2017). "Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies". J Clin Transl Hepatol. 5 (1): 67–75. doi:10.14218/JCTH.2016.00061. PMC 5411359. PMID 28507929.
- ↑ Day, CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut. 2002 May; 50(5): 585–588.
- ↑ "ac-els-cdn-com.ezp-prod1.hul.harvard.edu" (PDF).